NDT Advance Access originally published online on December 6, 2005
Nephrology Dialysis Transplantation 2006 21(2):273-280; doi:10.1093/ndt/gfi246
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Editorial Review
Hyperphosphataemia and related mortality
Centre de Rein Artificiel de Tassin, Tassin la demi-lune, France
Correspondence and offprint requests to: Guillaume Jean, Centre de Rein Artificiel de Tassin, Tassin la demi-lune, France. Email: Gjean14357@aol.com or guillaume.jean@wanadoo.fr
Keywords: hyperphosphataemia; phosphate binders; vitamin D
| The first 150 words of the full text of this article appear below. |
End-stage renal disease (ESRD) patients have a dramatically higher risk of death compared with the general population [1]. In 1998, Block et al. showed that hyperphosphataemia and a high calcium x phosphorus product are independently associated with mortality in dialysis patients [2]. More recently, based on a large cohort, the same authors have confirmed these findings adding hypercalcaemia and severe hyperparathyroidism (HPT) to risk factors for mortality. They have shown that the mortality risk associated with disorders of mineral metabolism is higher than that associated with a low urea reduction ratio (URR) and anaemia [3]. These risk factors for mortality were confirmed in the DOPPS study [4] and more recently in the USRDS waves study [5]. The excess mortality observed in dialysis patients is mainly of cardiovascular origin and it has been associated with cardiovascular calcifications in ESRD patients [
 |
Causes of, and therapy for, hyperphosphataemia |
|---|
Dietary phosphate intake
Phosphate binders
Bone-related hyperphosphataemia and vitamin D
Dialysis prescription
|
Characteristics of hyperphosphataemic patients in Tassin |
|---|
|
Conclusion |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Jean, J.-C. Terrat, T. Vanel, J.-M. Hurot, C. Lorriaux, B. Mayor, and C. Chazot High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2792 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jean, E. Bresson, J.-C. Terrat, T. Vanel, J.-M. Hurot, C. Lorriaux, B. Mayor, and C. Chazot Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences Nephrol. Dial. Transplant., March 1, 2009; 24(3): 948 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jean, J.-C. Terrat, T. Vanel, J.-M. Hurot, C. Lorriaux, B. Mayor, and C. Chazot Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3670 - 3676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Noordzij, J. C. Korevaar, E. W. Boeschoten, F. W. Dekker, W. J. Bos, and R. T. Krediet Hyperphosphataemia and related mortality Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2676 - 2677. [Full Text] [PDF]
|
|